JP2022522602A - 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 - Google Patents
標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 Download PDFInfo
- Publication number
- JP2022522602A JP2022522602A JP2021539352A JP2021539352A JP2022522602A JP 2022522602 A JP2022522602 A JP 2022522602A JP 2021539352 A JP2021539352 A JP 2021539352A JP 2021539352 A JP2021539352 A JP 2021539352A JP 2022522602 A JP2022522602 A JP 2022522602A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cancer
- electrical properties
- frequency
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 131
- 201000011510 cancer Diseases 0.000 title claims abstract description 124
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 116
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 44
- 230000005684 electric field Effects 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims description 77
- 230000008569 process Effects 0.000 claims description 21
- 210000004881 tumor cell Anatomy 0.000 description 19
- 238000005259 measurement Methods 0.000 description 14
- 230000003287 optical effect Effects 0.000 description 10
- 230000000704 physical effect Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36002—Cancer treatment, e.g. tumour
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36031—Control systems using physiological parameters for adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/22—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
- G01N27/221—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance by investigating the dielectric properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48728—Investigating individual cells, e.g. by patch clamp, voltage clamp
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrotherapy Devices (AREA)
- Neurology (AREA)
- Human Computer Interaction (AREA)
Abstract
Description
本出願は、全体として参照により本明細書に組み込まれている、2019年2月26日に出願した米国仮出願第62/810,823号の利益を主張するものである。
測定された電気特性をどのように使用して、対象のがんを治療するために対象に印加されるべきTTフィールドの周波数を決定することができるかを確立するために、様々な腫瘍タイプ由来の18種の細胞株のベースラインの電気特性(誘電率及び導電率)を、3DEP(商標)細胞分析システムを使用して決定した。これら18種の細胞株のなかで、まず、これらの細胞株のうちの10種(HepG2、A549、H1299、MDA231、LLC-1、C3A、AGS、KATO III、H2052、及びRN5)が、150kHzの周波数でTTフィールドを使用する治療に対して最も影響を受けやすく、これらの細胞株のうちの8種(A172、A2780、U87、A375、LN18、LN229、DKMG、及びU251)が、200kHzの周波数でTTフィールドを使用する治療に対して最も影響を受けやすいことを確証した。18種の細胞株すべてについて最適なTTフィールド周波数を、Inovitro(商標)システムを使用して様々な周波数でのTTフィールドの細胞傷害効果を試験することによって、決定した。
他の実施形態において、任意の特定の対象個人の体内のがん細胞の電気特性に基づき、TTフィールド治療が該任意の特定の対象個人に対して有効となるかどうかについて、予測を行うことができる。該特定の対象個人からのがん細胞の電気特性は、周波数を選択する実施形態に関して上述した手法のうちのいずれが(例えば、3DEP(商標))を使用して決定することができる。
Claims (18)
- がん性組織を有する対象におけるがんを治療する方法であって、
対象から、少なくとも1つのがん細胞を有するがん性組織の試料を得る工程、
該少なくとも1つのがん細胞の電気特性を決定する工程、
決定された電気特性に基づき、がんを治療するために対象に印加する交流電場の周波数を決定する工程、及び
決定された交流電場の周波数で対象に交流電場を印加することによってがんを治療する工程
を含む方法。 - 電気特性を決定する工程が、35kHz未満の複数の周波数の各々において、少なくとも1つのがん細胞の誘電泳動力を測定することを含む、請求項1に記載の方法。
- 周波数を決定する工程が、決定された電気特性に一致する既知の電気特性を有する参照がん細胞の処理において有効である周波数を選択することを含む、請求項1に記載の方法。
- 電気特性を決定する工程が、細胞膜静電容量を決定することを含む、請求項1に記載の方法。
- がん性組織を有する対象におけるがんを治療する方法であって、
対象から、少なくとも1つのがん細胞を有するがん性組織の試料を得る工程、
該少なくとも1つのがん細胞の少なくとも1つの物理的パラメーターを測定する工程であって、該少なくとも1つのがん細胞の電気特性が、該少なくとも1つの物理的パラメーターから決定され得る工程、
測定された少なくとも1つの物理的パラメーターに基づき、がんを治療するために対象に印加する交流電場の周波数を決定する工程、及び
決定された交流電場の周波数で対象に交流電場を印加することによってがんを治療する工程
を含む方法。 - 少なくとも1つのがん細胞の細胞膜静電容量が、少なくとも1つの物理的パラメーターから決定され得る、請求項5に記載の方法。
- がん性組織を有する対象におけるがんを治療する方法であって、
対象から、少なくとも1つのがん細胞を有するがん性組織の試料を得る工程、
該少なくとも1つのがん細胞の電気特性を決定する工程、
決定された電気特性に基づき、対象への交流電場の印加ががんを治療するのに有効となるかどうかを予測する工程、及び
予測が、対象への交流電場の印加ががんを治療するのに有効となることを示す場合、対象に交流電場を印加することによってがんを治療する工程
を含む方法。 - 電気特性を決定する工程が、35kHz未満の複数の周波数の各々において、少なくとも1つのがん細胞の誘電泳動力を測定することを含む、請求項7に記載の方法。
- 予測する工程が、決定された電気特性に一致する電気特性を有する参照がん細胞が、交流電場を使用する治療に対して感受性であるかどうかに基づくものである、請求項7に記載の方法。
- 電気特性を決定する工程が、細胞膜静電容量を決定することを含む、請求項7に記載の方法。
- がん性組織を有する対象におけるがんを治療する方法であって、
対象から、少なくとも1つのがん細胞を有するがん性組織の試料を得る工程、
該少なくとも1つのがん細胞の少なくとも1つの物理的パラメーターを測定する工程であって、該少なくとも1つのがん細胞の電気特性が、該少なくとも1つの物理的パラメーターから決定され得る工程、
測定された少なくとも1つの物理的パラメーターに基づき、対象への交流電場の印加ががんを治療するのに有効となるかどうかを予測する工程、及び
予測が対象への交流電場の印加ががんを治療するのに有効となることを示す場合、対象に交流電場を印加することによってがんを治療する工程
を含む方法。 - 少なくとも1つのがん細胞の細胞膜静電容量が、少なくとも1つの物理的パラメーターから決定され得る、請求項11に記載の方法。
- がん性組織を有する対象におけるがんを治療するために使用される、交流電場の周波数を選択する方法であって、
対象から得られたがん性組織の試料から摘出された少なくとも1つのがん細胞の電気特性を決定する工程、及び
決定された電気特性に基づき、がんを治療するために対象に印加する交流電場の周波数を決定する工程
を含む方法。 - 電気特性を決定する工程が、35kHz未満の複数の周波数の各々において、少なくとも1つのがん細胞の誘電泳動力を測定することを含む、請求項13に記載の方法。
- 周波数を決定する工程が、決定された電気特性に一致する既知の電気特性を有する参照がん細胞の処置において有効な周波数を選択することを含む、請求項13に記載の方法。
- 電気特性を決定する工程が、細胞膜静電容量を決定することを含む、請求項13に記載の方法。
- がん性組織を有する対象におけるがんを治療するために使用される、交流電場の周波数を選択する方法であって、
対象から得られたがん性組織の試料から摘出された少なくとも1つのがん細胞の少なくとも1つの物理的パラメーターを測定する工程であって、該少なくとも1つのがん細胞の電気特性が、該少なくとも1つの物理的パラメーターから決定され得る工程、及び
測定された少なくとも1つの物理的パラメーターに基づき、がんを治療するために対象に印加する交流電場の周波数を決定する工程
を含む方法。 - 少なくとも1つのがん細胞の細胞膜静電容量が、少なくとも1つの物理的パラメーターから決定され得る、請求項17に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023111560A JP2023145480A (ja) | 2019-02-26 | 2023-07-06 | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962810823P | 2019-02-26 | 2019-02-26 | |
US62/810,823 | 2019-02-26 | ||
PCT/IB2020/051613 WO2020174403A1 (en) | 2019-02-26 | 2020-02-25 | Determining a frequency for ttfields treatment based on an electrical characteristic of targeted cancer cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023111560A Division JP2023145480A (ja) | 2019-02-26 | 2023-07-06 | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022522602A true JP2022522602A (ja) | 2022-04-20 |
Family
ID=69784486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539352A Pending JP2022522602A (ja) | 2019-02-26 | 2020-02-25 | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 |
JP2023111560A Pending JP2023145480A (ja) | 2019-02-26 | 2023-07-06 | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023111560A Pending JP2023145480A (ja) | 2019-02-26 | 2023-07-06 | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11554262B2 (ja) |
EP (2) | EP3930824B1 (ja) |
JP (2) | JP2022522602A (ja) |
KR (2) | KR20240013279A (ja) |
CN (1) | CN113573774A (ja) |
CA (1) | CA3127276A1 (ja) |
IL (1) | IL284284A (ja) |
WO (1) | WO2020174403A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10779875B2 (en) | 2013-05-06 | 2020-09-22 | Novocure Gmbh | Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment |
US10188851B2 (en) | 2015-10-28 | 2019-01-29 | Novocure Limited | TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements |
US10821283B2 (en) | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
CN110178029B (zh) | 2017-01-19 | 2021-11-16 | 诺沃库勒有限责任公司 | 用于在施加TTFields的同时在显微镜下观察细胞培养物的*** |
US11986647B2 (en) | 2018-09-07 | 2024-05-21 | Novocure Gmbh | Treating autoinflammatory and mitochondrial diseases using an alternating electric field |
CA3110448C (en) | 2018-11-19 | 2023-12-19 | Novocure Gmbh | Arrays for delivering tumor treating fields (ttfields) with selectively addressable sub-elements |
JP7246486B2 (ja) | 2019-01-08 | 2023-03-27 | ノボキュア ゲーエムベーハー | 腫瘍治療電場(ttfields)を使用した治療を計画するための異なるタイプの組織への画像のセグメンテーションの品質評価 |
CN114364432A (zh) | 2019-07-31 | 2022-04-15 | 诺沃库勒有限责任公司 | 经由埋入颅骨植入物中的电极施加肿瘤治疗场(TTField) |
US11890467B2 (en) | 2019-08-30 | 2024-02-06 | Novocure Gmbh | Delivering tumor treating fields (TTFields) to the neck |
WO2021137085A2 (en) | 2019-12-31 | 2021-07-08 | Novocure Gmbh | High voltage, high efficiency sine wave generator that prevents spikes during amplitude adjustments and switching of channels |
EP4212203A1 (en) | 2019-12-31 | 2023-07-19 | Novocure GmbH | Arrays for delivering tumor treating fields (ttfields) with individually accessible electrode elements and temperature sensors |
US11818943B2 (en) | 2020-06-25 | 2023-11-14 | Novocure Gmbh | Fabricating organic light emitting diodes (OLEDs) using tubulin |
US20230168242A1 (en) * | 2021-11-29 | 2023-06-01 | Novocure Gmbh | Methods of Reducing Ciliogenesis with Alternating Electric Fields |
WO2023187751A1 (en) * | 2022-03-31 | 2023-10-05 | Novocure Gmbh | Alternating electric field waveform for electrosensation reduction |
CN115554602B (zh) * | 2022-10-13 | 2023-10-27 | 云禾智能科技(天津)有限公司 | 一种结合交变电场和干扰电的肿瘤治疗仪 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7565205B2 (en) | 2000-02-17 | 2009-07-21 | Standen Ltd. | Treating a tumor or the like with electric fields at different orientations |
EP2335776A1 (en) | 2000-02-17 | 2011-06-22 | Yoram Palti | Method and apparatus for destroying dividing cells |
US7089054B2 (en) | 2002-10-02 | 2006-08-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
US7136699B2 (en) | 2002-10-02 | 2006-11-14 | Standen, Ltd. | Apparatus for destroying dividing cells |
US7016725B2 (en) | 2001-11-06 | 2006-03-21 | Standen Ltd. | Method and apparatus for destroying dividing cells |
US7599746B2 (en) | 2000-02-17 | 2009-10-06 | Standen Ltd | Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases |
US8175698B2 (en) | 2000-02-17 | 2012-05-08 | Novocure Ltd. | Treating bacteria with electric fields |
US6868289B2 (en) | 2002-10-02 | 2005-03-15 | Standen Ltd. | Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor |
US8447395B2 (en) | 2000-02-17 | 2013-05-21 | Novocure Ltd | Treating bacteria with electric fields |
US7344533B2 (en) | 2001-09-28 | 2008-03-18 | Angiodynamics, Inc. | Impedance controlled tissue ablation apparatus and method |
CA2590342C (en) | 2004-12-07 | 2016-09-20 | Standen Ltd. | Electrodes for applying an electric field in-vivo over an extended period of time |
WO2006085150A2 (en) | 2004-12-27 | 2006-08-17 | Standen Ltd. | Treating a tumor or the like with electric fields at different orientations |
PT1933937E (pt) | 2005-10-03 | 2015-04-23 | Novocure Ltd | Optimização de características de um campo eléctrico para aumentar o efeito do campo em células proliferantes |
US8019414B2 (en) | 2006-04-05 | 2011-09-13 | Novocure Ltd. | Treating cancer using electromagnetic fields in combination with other treatment regimens |
WO2009044289A1 (en) | 2007-03-06 | 2009-04-09 | Novocure Ltd. | Treating cancer using electromagnetic fields in combination with photodynamic therapy |
EP2183024B1 (en) | 2007-08-14 | 2019-05-15 | Novocure Ltd. | Treating parasites with electric fields |
US8715203B2 (en) | 2007-09-17 | 2014-05-06 | Novocure Limited | Composite electrode |
US10779875B2 (en) | 2013-05-06 | 2020-09-22 | Novocure Gmbh | Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment |
US9655669B2 (en) * | 2013-05-06 | 2017-05-23 | Novocure Limited | Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment |
US20190117963A1 (en) | 2014-07-25 | 2019-04-25 | Loyalty Based Innovations, LLC | Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields |
US9910453B2 (en) | 2015-09-25 | 2018-03-06 | Novocure Limited | High voltage, high efficiency sine wave generator with pre-set frequency and adjustable amplitude |
US10188851B2 (en) | 2015-10-28 | 2019-01-29 | Novocure Limited | TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements |
US10821283B2 (en) | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
KR102669633B1 (ko) | 2016-06-30 | 2024-05-24 | 노보큐어 리미티드 | 신체에 대한 종양 치료장의 길이 방향 전달을 위한 어레이들 |
US20180008708A1 (en) | 2016-07-10 | 2018-01-11 | Novocure Limited | Synchronizing Tumor Cells to the G2/M Phase Using TTFields Combined with Taxane or Other Anti-Microtubule Agents |
EP4218908A1 (en) | 2016-08-18 | 2023-08-02 | Novocure GmbH | Temperature measurement in arrays for delivering ttfields |
AU2017377003B2 (en) | 2016-12-13 | 2022-05-19 | Novocure Gmbh | Treating patients with TTFields with the electrode positions optimized using deformable templates |
CN110178029B (zh) | 2017-01-19 | 2021-11-16 | 诺沃库勒有限责任公司 | 用于在施加TTFields的同时在显微镜下观察细胞培养物的*** |
US10758151B2 (en) * | 2017-01-23 | 2020-09-01 | NovaScan, Inc. | Techniques for detecting cancerous cells in excised tissue samples using impedance detection |
US9934364B1 (en) * | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
EP3773726B1 (en) | 2018-04-09 | 2024-06-05 | Novocure GmbH | Treating tumors with ttfields and an aurora kinase inhibitor |
KR20200141478A (ko) | 2018-04-10 | 2020-12-18 | 지브 봄존 | 서로 다른 반복 시간을 가지는 두 개의 MRI 이미지들로부터 얻어진 1MHz 미만 저주파 교류 전도도 추산치 |
SG11202012597UA (en) | 2018-07-03 | 2021-01-28 | Edwin Chang | Using alternating electric fields to increase cell membrane permeability |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
KR102607603B1 (ko) | 2018-07-18 | 2023-11-29 | 노보큐어 게엠베하 | 종양 치료장의 용량을 정량화하기 위한 전력 손실 밀도 및 관련 측정값의 사용 |
CN113908431A (zh) | 2018-08-23 | 2022-01-11 | 诺沃库勒有限责任公司 | 使用交变电场来提高血脑屏障的通透性 |
US11160977B2 (en) | 2018-09-04 | 2021-11-02 | Novocure Gmbh | Delivering tumor treating fields (TTFields) to the infratentorial brain |
US11020585B2 (en) | 2018-09-07 | 2021-06-01 | Novocure Gmbh | Treating autoimmune diseases using an alternating electric field to reduce the proliferation of t-cells |
US20200108031A1 (en) | 2018-10-05 | 2020-04-09 | Novocure Gmbh | Treating Tumors Using TTFields Combined with ABT-751 |
CN113164525A (zh) | 2018-10-23 | 2021-07-23 | 利兰·斯坦福青年大学托管委员会 | 在基于干细胞的疗法中使用交变电场预防和治疗畸胎瘤形成 |
JP7148722B2 (ja) | 2018-10-25 | 2022-10-05 | ゼーヴ・ボンゾン | 被験者の脊椎構造体に対する交番電界(例えばTTField)の送達 |
US20200146586A1 (en) | 2018-11-14 | 2020-05-14 | Novocure Gmbh | Creating Accurate Computational Head Models of Patients Using Datasets Combining MRI and CT Images |
CA3110448C (en) | 2018-11-19 | 2023-12-19 | Novocure Gmbh | Arrays for delivering tumor treating fields (ttfields) with selectively addressable sub-elements |
BR112021004336A2 (pt) | 2018-11-29 | 2021-08-17 | Novocure Gmbh | matrizes de transdutor com flexibilidade melhorada para entregar ttfields (campos de tratamento de tumor) |
-
2020
- 2020-02-25 CN CN202080016983.1A patent/CN113573774A/zh active Pending
- 2020-02-25 KR KR1020247001811A patent/KR20240013279A/ko not_active Application Discontinuation
- 2020-02-25 US US16/800,737 patent/US11554262B2/en active Active
- 2020-02-25 KR KR1020217029119A patent/KR20210126083A/ko not_active Application Discontinuation
- 2020-02-25 WO PCT/IB2020/051613 patent/WO2020174403A1/en unknown
- 2020-02-25 JP JP2021539352A patent/JP2022522602A/ja active Pending
- 2020-02-25 CA CA3127276A patent/CA3127276A1/en active Pending
- 2020-02-25 EP EP20710600.6A patent/EP3930824B1/en active Active
- 2020-02-25 EP EP21208106.1A patent/EP3974022B1/en active Active
-
2021
- 2021-06-22 IL IL284284A patent/IL284284A/en unknown
-
2023
- 2023-07-06 JP JP2023111560A patent/JP2023145480A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023145480A (ja) | 2023-10-11 |
IL284284A (en) | 2021-08-31 |
EP3974022A1 (en) | 2022-03-30 |
KR20210126083A (ko) | 2021-10-19 |
EP3974022B1 (en) | 2024-04-17 |
WO2020174403A1 (en) | 2020-09-03 |
CN113573774A (zh) | 2021-10-29 |
CA3127276A1 (en) | 2020-09-03 |
EP3930824C0 (en) | 2024-04-03 |
US11554262B2 (en) | 2023-01-17 |
US20200269042A1 (en) | 2020-08-27 |
EP3930824A1 (en) | 2022-01-05 |
EP3930824B1 (en) | 2024-04-03 |
EP3974022C0 (en) | 2024-04-17 |
KR20240013279A (ko) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022522602A (ja) | 標的がん細胞の電気特性に基づくttフィールド治療のための周波数の決定 | |
Cavallaro et al. | Label-free surface protein profiling of extracellular vesicles by an electrokinetic sensor | |
Greening et al. | Proteomic insights into extracellular vesicle biology–defining exosomes and shed microvesicles | |
Borisov et al. | Signaling pathways activation profiles make better markers of cancer than expression of individual genes | |
WO2020023420A3 (en) | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage | |
Backes et al. | Immunogenicity of autoantigens | |
JP2015533084A5 (ja) | ||
KR20180072717A (ko) | 핵산 시퀀싱을 위한 장치, 시스템 및 방법 | |
WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
Penninckx et al. | Quantification of radiation-induced DNA double strand break repair foci to evaluate and predict biological responses to ionizing radiation | |
Zhuang et al. | The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel | |
JP2012525818A5 (ja) | ||
Zhu et al. | Proteins and an inflammatory network expressed in colon tumors | |
Khanfar et al. | Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses | |
Sala et al. | Global serum profiling: an opportunity for earlier cancer detection | |
Leguèbe et al. | Mathematical model for transport of DNA plasmids from the external medium up to the nucleus by electroporation | |
Du et al. | Power normalization for mass spectrometry data analysis and analytical method assessment | |
Mehta et al. | Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade | |
Kaushik et al. | Advancements in Characterization Techniques of Biopolymers: Cyclic Voltammetry, Gel Electrophoresis, Circular Dichroism and Fluorescence Spectroscopy | |
MacKay et al. | Simulating electrical properties of interdigitated electrode designs for impedance-based biosensing applications | |
Tutanov et al. | Search for breast cancer proteomic markers in total blood exosomes | |
Zhu et al. | Emerging applications of tumour-educated platelets in the detection and prognostication of ovarian cancer | |
TW201243356A (en) | Hall effect measuring device with light guiding measuring function | |
Weyland et al. | Dynamic DNA Damage and Repair Modeling: Bridging the Gap Between Experimental Damage Readout and Model Structure | |
Ganesh et al. | Mapping Immune–Tumor Bidirectional Dialogue Using Ultrasensitive Nanosensors for Accurate Diagnosis of Lung Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230306 |